Barclays PLC Acquires 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Barclays PLC raised its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 105.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,915 shares of the company’s stock after acquiring an additional 48,614 shares during the period. Barclays PLC owned about 0.17% of Olema Pharmaceuticals worth $1,133,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in OLMA. Point72 Asset Management L.P. increased its stake in shares of Olema Pharmaceuticals by 14.8% in the third quarter. Point72 Asset Management L.P. now owns 3,687,374 shares of the company’s stock valued at $44,027,000 after buying an additional 475,447 shares in the last quarter. State Street Corp raised its stake in shares of Olema Pharmaceuticals by 1.1% during the third quarter. State Street Corp now owns 1,969,963 shares of the company’s stock worth $23,521,000 after buying an additional 21,986 shares during the last quarter. Candriam S.C.A. grew its holdings in Olema Pharmaceuticals by 199.9% during the 2nd quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock worth $11,454,000 after acquiring an additional 705,655 shares during the period. Wellington Management Group LLP boosted its position in shares of Olema Pharmaceuticals by 10.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares during the last quarter. Finally, Great Point Partners LLC lifted its stake in Olema Pharmaceuticals by 25.5% in the third quarter. Great Point Partners LLC now owns 1,000,000 shares of the company’s stock valued at $11,940,000 after buying an additional 203,120 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Insider Activity at Olema Pharmaceuticals

In other news, Director G. Walmsley Graham sold 700,761 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $6.75, for a total transaction of $4,730,136.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sean Bohen sold 52,328 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.37, for a total value of $490,313.36. Following the completion of the transaction, the chief executive officer now owns 298,836 shares in the company, valued at approximately $2,800,093.32. The trade was a 14.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 773,797 shares of company stock valued at $5,414,609 in the last quarter. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Stock Down 2.7 %

Shares of Olema Pharmaceuticals stock opened at $6.15 on Monday. The firm’s 50-day moving average price is $9.59 and its two-hundred day moving average price is $11.45. The company has a market capitalization of $352.38 million, a price-to-earnings ratio of -2.81 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a 12-month low of $5.56 and a 12-month high of $16.77.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $27.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.